CTRI/2024/01/061161已完成不适用
A Multicenter, Randomized, Double-Blind, Three-Arm, Placebo-Controlled, Parallel Design, Study to Evaluate the Efficacy and Safety of Ketoconazole 2% Shampoo of Encube Ethicals Private Limited, India with Ketoconazole Shampoo, 2% of Padagis (Perrigo) Allegan, MI 49010 in Subjects with Tinea Versicolor.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 425
- 试验地点
- 15
- 主要终点
- 1. To evaluate bioequivalence (with clinical endpoint) of test product (Ketoconazole 2% Shampoo) of Encube Ethicals Private Limited, India with reference product (Ketoconazole Shampoo, 2%) of Padagis (Perrigo) Allegan, MI 49010 in subjects with tinea versicolor.
研究概览
简要总结
A study is A Multicenter, Randomized, Double-Blind, Three-Arm, Placebo-Controlled, Parallel Design study. This clinical trial intended to Evaluate the Efficacy and Safety of Ketoconazole 2% Shampoo of Encube Ethicals Private Limited, India with Ketoconazole Shampoo, 2% of Padagis (Perrigo) Allegan, MI 49010 in Subjects with Tinea Versicolor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •Male or non-pregnant, non-lactating female subjects of 18 to 65 years of age.
- •Subject with a clinical diagnosis of tinea versicolor and both of the following: a. A combined severity score of at least 4, with at least one of the following signs and symptoms rated at least 2, using the following scale: Signs/symptoms Scale desquamation/scaling.
- •0 equals to absent pruritus/itching.
- •1 equals to mild erythema.
- •2 equals to moderate & 3 equal to severe b. Presence of infection with Malassezia furfur (Pityrosporum orbiculare or P. ovale) confirmed by a positive KOH cellophane tape test showing the characteristic “spaghetti and meatballs†appearance of the round budding yeast cells and short hyphae.
- •Subject able to understand the investigational nature of this study and provide written informed consent prior to screening.
- •Female of childbearing potential, have a negative urine pregnancy test and willing to use an acceptable form of birth control including abstinence during the study.
- •Able to comply with study requirements in the opinion of Investigator.
- •Agree not to take a shower, bath, or swim, for at least 4 hours before all study visits
- •Agree to use only non-medicated shampoos and soaps during the entire study period.
排除标准
- •Subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •Has recent history or evidence of other fungal infections, including oral, vaginal or chronic mucocutaneous candidiasis, systemic fungal infections or dermatophyte infections that may interfere with assessment of tinea versicolor.
- •Use of any systemic antifungals (oral or injectable), corticosteroids or immunosuppressive drugs within 30 days prior to randomization.
- •Any eye disease that could be irritated by shampoo.
- •Subject with known history of uncontrolled diabetes (based on HbA1c report [greater than 7%] within last 3 months) or expected change in anti-diabetic medication during study or within last 1 month.
- •Use of any prescription or over the counter (OTC), topical antifungal, anti-pruritus, corticosteroid, selenium sulfide or zinc pyrithione preparations within 14 days prior to randomization or used antihistamines that may interfere with the subjects ability to experience cutaneous sensations within 24 hours prior to randomization, unless on a stable dose of antihistamine for at least 30 days.
- •Any known hypersensitivity or allergy to ketoconazole or any other inactive ingredients used in the study products or other imidazole antifungals or other shampoos, soaps or cosmetics.
- •Treatment for tinea versicolor within the past six months that has been unresponsive to prescription topical or oral antifungals.
- •History of alcohol or other substance abuse within the last one year.
- •Any other clinical investigation using experimental drug within past 30 days of prior to randomization.
- •Institutionalized subject.
- •Live in the same household as currently enrolled subject or in the same household of a subject who has previously participated in the study.
- •Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities or on any medication that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into the trial.
结局指标
主要结局
1. To evaluate bioequivalence (with clinical endpoint) of test product (Ketoconazole 2% Shampoo) of Encube Ethicals Private Limited, India with reference product (Ketoconazole Shampoo, 2%) of Padagis (Perrigo) Allegan, MI 49010 in subjects with tinea versicolor.
时间窗: 4 Week(±4 days)
2. To evaluate superiority of test and reference product with placebo in subjects with tinea versicolor.
时间窗: 4 Week(±4 days)
次要结局
- 1. To assess safety and tolerability of study treatments.
研究者
Dr Dharmesh Domadia
Cliantha Research Limited
研究点 (15)
Loading locations...
相似试验
进行中（未招募）
不适用
Study to evaluate the bioequivalence of Diclofenac diethylamine gel, 1.16% in subjects with Osteoarthritis Degenerative joint disease of the knee.CTRI/2023/12/060871Encube Ethical Private Limited, India942
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of Diltiazem Gel in Subjects with Chronic Anal Fissure.CTRI/2024/12/078489Morningside Healthcare266
尚未招募
不适用
Evaluate the bioequivalence with the clinical endpoint of ferric citrate tablet in patients with chronic kidney disease not on dialysis (CKD-NDD)CTRI/2024/10/076004Mylan Laboratories Limited423
已完成
不适用
clinical Study of Pimecrolimus cream in Atopic dermatitis patients in IndiaCTRI/2024/03/063709Encube Ethicals Private Limited690
已完成
不适用
Clinical endpoint trial to evaluate the bioequivalence of Tapinarof cream 1%CTRI/2024/10/075933Mylan Laboratories Ltd450